IMPACT OF GUSELKUMAB INDUCTION THERAPY ON HISTOLOGIC AND COMBINED HISTOLOGIC AND ENDOSCOPIC OUTCOMES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: WEEK 12 RESULTS FROM THE PHASE 3 QUASAR INDUCTION STUDY

Julian Panés  ¹     Bruce E. Sands  ²     Laurent Peyrin-Biroulet  ³     Shadi Yarandi  ⁴     Gary KH Huang  ⁴     Matthew Germinaro  ⁴     Sunandini Sridhar  ⁴     Patrick Branigan  ⁴     Ye Miao  ⁴     Hongyan Zhang  ⁴     Xavier Hebuterne  ⁵     Tibor Gyokeres  ⁶     Fumihito Hirai  ⁷     Tadakazu Hisamatsu  ⁸     David T. Rubin  ⁹     Brian G. Feagan  ^10    
1 Hospital Clínic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain
² Icahn School of Medicine at Mount Sinai, New York, United States
³ Nancy University Hospital, Université de Lorraine, Nancy, France
⁴ Janssen Research & Development, LLC, Spring House, United States
⁵ CHU de Nice and University Côte d’Azur, Nice, France
⁶ North-Pest Central Hospital, Military Hospital, Budapest, Hungary
⁷ Fukuoka University Hospital, Fukuoka, Japan
⁸ Kyorin University, Tokyo, Japan
⁹ University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, United States
¹⁰ Alimentiv Inc, London, Canada

Topic
Endoscopy, Histopathology, IBD

Session
IL-23-Blockers in IBD: Part 2

Conference
UEG Week Copenhagen 2023

Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)